The U.S. Food and Drug Administration (FDA) has approved bemotrizinol, marking the first time in nearly three decades that a new active sunscreen ingredient has been cleared for use in the United States. This regulatory milestone, which follows a long-standing impasse in American sun protection innovation, allows for a more modern, broad-spectrum filter—known as BEMT—to reach the domestic market after years of widespread use in Europe and Asia. The approval process was catalyzed by congressional mandates to modernize the agency’s oversight of over-the-counter (OTC) sunscreen products, providing a long-awaited regulatory pathway for advanced chemical filters.
For decades, the U.S. market has been constrained by a regulatory framework that categorizes sunscreens as drugs rather than cosmetics, a classification that requires rigorous clinical testing and administrative review for any new active ingredient. This distinction has effectively frozen innovation since the late 1990s, leaving American consumers with fewer options compared to international counterparts. According to the FDA’s regulatory history, the agency’s assessment of sunscreen safety and efficacy is governed by the Federal Food, Drug, and Cosmetic Act, which necessitates that manufacturers provide extensive data to prove that new filters are both safe and effective for daily use.
Why the Approval of Bemotrizinol Matters
The introduction of BEMT is significant because the ingredient provides broad-spectrum protection against both UVA and UVB rays while maintaining a more favorable texture than traditional mineral-based products. Unlike zinc oxide or titanium dioxide, which often leave a white, chalky residue on the skin, bemotrizinol is known for being “cosmetically elegant,” meaning it is transparent and lightweight upon application. Dermatologists suggest that this improvement in user experience may help address the decline in consistent sunscreen use, as consumers are more likely to apply products that do not interfere with their daily appearance or comfort.
The regulatory shift that allowed for this approval traces back to the Coronavirus Aid, Relief, and Economic Security (CARES) Act, passed by Congress in 2020. This legislation included provisions specifically aimed at reforming the FDA’s monograph process for nonprescription drugs. By streamlining how the agency evaluates new sunscreen ingredients, the law provided a clearer, more predictable path for manufacturers like DSM Nutritionals to submit their safety data for review. This legislative action was essential in moving the needle after years of industry and public health advocacy.
Addressing Safety Concerns and Market Skepticism
Public confidence in sunscreens has faced challenges since 2019, when the FDA initiated a review of existing chemical filters, requesting additional safety data for many widely used ingredients. This period of uncertainty, coupled with studies published in journals such as JAMA, revealed that certain chemical sunscreen components could be absorbed into the bloodstream at levels exceeding proposed thresholds. These findings fueled a rise in sunscreen skepticism, with some consumers turning toward unproven, DIY alternatives, despite the well-documented risks of skin cancer associated with inadequate UV protection.
Bemotrizinol, however, has been used internationally for decades and has accumulated a robust body of evidence demonstrating its safety profile. Unlike the ingredients that sparked the 2019 safety concerns, preliminary clinical data suggests that BEMT does not permeate the skin in significant concentrations. This distinction is expected to be a primary selling point for manufacturers looking to rebuild consumer trust. The Environmental Working Group (EWG) has publicly supported the approval, describing the move as a necessary step in ensuring that American consumers have access to the highest standards of sun protection available globally.
What Happens Next for Consumers
DSM Nutritionals holds exclusive rights for the next 18 months to market its proprietary formulation, Parsol Shield, which utilizes bemotrizinol. After this period, other manufacturers will be permitted to incorporate the ingredient into their own sunscreen products. Consumers should begin looking for “bemotrizinol” or “BEMT” on the active ingredients label of their sunscreens as new products hit retail shelves.
Health experts continue to emphasize that, regardless of the ingredients used, the most important factor in preventing skin cancer—the most common form of cancer in the U.S.—remains consistent application and the use of broad-spectrum products with an SPF between 30 and 50. While BEMT offers a more modern option, it does not replace the need for regular reapplication or other sun-safe practices, such as seeking shade and wearing protective clothing. The FDA maintains an ongoing portal for consumer updates on sun safety, which provides the most current guidance on product selection and usage.
As the market integrates this new filter, regulators are expected to continue monitoring long-term safety data. Any further updates regarding sunscreen ingredient monographs will be posted through the FDA’s official regulatory channels. Please share your thoughts on these changes or your experiences with new sun protection formulations in the comments section below.
Keep reading